- Home
- BFST vs XERS Comparison
BFST vs XERS Comparison
Compare BFST & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | XERS |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 1.0B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFST | XERS |
|---|---|---|
| Price | $27.98 | $6.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $32.75 | $10.83 |
| AVG Volume (30 Days) | 141.8K | ★ 1.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 100.00 |
| EPS | ★ 0.68 | 0.01 |
| Revenue | $10,704,000.00 | ★ $49,590,000.00 |
| Revenue This Year | $22.71 | $34.37 |
| Revenue Next Year | $5.02 | $22.86 |
| P/E Ratio | ★ $41.16 | $638.48 |
| Revenue Growth | 1.20 | ★ 142.67 |
| 52 Week Low | $22.56 | $4.30 |
| 52 Week High | $30.32 | $10.08 |
Technical Indicators
Market Signals| Indicator | BFST | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 49.57 |
| Support Level | $26.73 | $5.79 |
| Resistance Level | $28.74 | $6.41 |
| Average True Range (ATR) | 0.53 | 0.32 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 75.72 | 28.51 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.